Challenges in Adopting Targeted Therapies for BRAF Alterations


Experts discuss the challenges in adopting targeted therapies like BRAF/MEK inhibitors for BRAF-altered gliomas and gangliogliomas and strategies to facilitate their integration into practice.

Related Videos
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Video  10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"
Video  9 - "Additional Second-Line Treatments for HCC"
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"
A panel of 4 experts on colorectal cancer
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Video 7 - "Comorbidity Considerations for HCC Treatment"
Video 8 - "Future Outlook for RET Fusion-Targeted Therapies"
Related Content